EW
Edwards Lifesciences Corp

4,903
Loading...
Loading...
News
all
press releases
Top Stock Reports for Apple, Novartis & Charles Schwab
Apple grows Services to 1B+ paid subscribers, while Novartis lifts guidance and Schwab rides higher rates to asset gains.
Zacks·14d ago
News Placeholder
More News
News Placeholder
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
Zacks·20d ago
News Placeholder
Nvidia, Citi, AT&T, Lucid, Edwards Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
vidia continues to make waves and struggling electric-vehicle maker Lucid’s reacted to the news of an imminent reverse stock split.
Stocktwits·27d ago
News Placeholder
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Zacks·1mo ago
News Placeholder
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
Zacks·1mo ago
News Placeholder
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
Zacks·2mo ago
News Placeholder
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Zacks·2mo ago
News Placeholder
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Zacks·2mo ago
News Placeholder
Compared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key Metrics
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·2mo ago
News Placeholder
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.
Zacks·2mo ago

Latest EW News

View

Advertisement. Remove ads.

Advertisement. Remove ads.